Germany - CureVac N.V. (Nasdaq: CVAC) ('CureVac'), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ('mRNA'), today announced that the nullity action filed by BioNTech SE against the German part of CureVac patent EP 1 857 122 B1 was granted by the German Federal Patent Court.

CureVac will appeal before the German Federal Court of Justice.

The ruling represents a first decision on validity in ongoing patent litigation between CureVac and BioNTech SE in Germany, which involves a total of eight CureVac intellectual property rights. Proceedings continue regarding the seven remaining rights, for which validity, infringement and potential damages will be decided individually. Following today's decision, a ruling on infringement of the German part of EP 1 857 122 B1, scheduled for December 28, 2023, before the Regional Court Dusseldorf, will likely be postponed.

'We consider the patent court's decision unfortunate also in view of the positive preliminary opinion on EP 1 857 122 B1 the court provided earlier this year. The decision is only one of many that will be made regarding the use of CureVac's intellectual property in the development of Comirnaty. We remain highly confident that our pioneering role in mRNA technology and continuing innovation in the field made essential contributions to safe and efficacious COVID-19 vaccines,' said Dr. Alexander Zehnder, Chief Executive Officer of CureVac. 'While we do not seek to diminish the value of mRNA vaccines in changing the course of the COVID-19 pandemic, we strongly believe that CureVac's role in laying the scientific groundwork for those vaccines needs to be recognized. We will continue to defend our claim for recognition and fair compensation and will take appropriate action by appealing this decision.'

CureVac is represented in Germany by Oliver Jan Jungst from Bird & Bird LLP and Andreas Graf von Stosch from Graf von Stosch Patentanwaltsgesellschaft and represented in the U.S. by Mark H. Izraelewicz from Marshall, Gerstein & Borun LLP.

About CureVac

CureVac (Nasdaq: CVAC) is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing, optimizing, and manufacturing this versatile biological molecule for medical purposes. The principle of CureVac's proprietary technology is the use of optimized mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. In July 2020, CureVac entered in a collaboration with GSK to jointly develop new products in prophylactic vaccines for infectious diseases based on CureVac's second-generation mRNA technology. This collaboration was later extended to the development of second-generation COVID-19 vaccine candidates, and modified mRNA vaccine technologies. Based on its proprietary technology, CureVac has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac N.V. has its headquarters in Tubingen, Germany, and has more than 1,100 employees across its sites in Germany, the Netherlands, Belgium, Switzerland and the U.S.

Contact:

Dr. Sarah Fakih

Tel: +49 7071 9883-1298

(C) 2023 Electronic News Publishing, source ENP Newswire